The US-based technology platform for drug development backed by GloxoSmithKline's SR One has used extension financing to bump up its latest funding round to $19m.

SpringLeaf Therapeutics, a US-based technology platform, has raised $19m after securing an additional $4m investment for its latest round.

US based life sciences specialist Excel Venture Management provided the additional funds for the Series B round, after SpringLeaf held a first close in May. The round was led by GlaxoSmithKline’s SR One.

Venture capital firms Flybridge Capital Partners and North Bridge Venture Partners reinvested in the round, having invested $12m in its A round in 2008. This means the…